(:NGM)

Apr 05, 2024 09:19 am ET
NGM Bio Announces Closing of Tender Offer
NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column...
Mar 22, 2024 06:59 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI
NEW YORK, March 22, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 22, 2024 01:34 pm ET
Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn...
Mar 21, 2024 11:23 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: HireRight Holdings Corporation (NYSE:...
Mar 21, 2024 03:30 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 20, 2024 07:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 19, 2024 05:30 pm ET
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2...
Mar 19, 2024 03:30 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 18, 2024 03:30 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 16, 2024 11:09 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM, SCTL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: HireRight Holdings Corporation (NYSE:...
Mar 14, 2024 01:30 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 13, 2024 11:44 am ET
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP. Under the terms of the proposed transaction, shareholders of NGM will receive $1.55 in cash for each share of NGM that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Mar 12, 2024 05:45 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 11, 2024 04:05 pm ET
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided recent business highlights and reported financial results for the fourth...
Mar 11, 2024 03:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 09, 2024 08:58 am ET
INVESTIGATION UPDATE: Halper Sadeh LLC Investigates CHRD, AA, NGM, SCTL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chord Energy Corporation (NASDAQ:...
Mar 04, 2024 05:00 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NGM Biopharmaceuticals, Inc. ("NGM Bio" or "the Company") (NASDAQ:NGM) for potential breaches of fiduciary duty on the part of its directors and management.
Mar 02, 2024 10:40 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AA, NGM, KNTE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alcoa Corporation (NYSE: AA)’s merger...
Feb 28, 2024 12:00 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, FREE, NGM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Catalent, Inc. (NYSE: CTLT)’s sale to...
Feb 27, 2024 04:10 pm ET
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP. Under the terms of the proposed transaction, shareholders of NGM will receive $1.55 in cash for each share of NGM that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Feb 26, 2024 09:15 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates NGM, AA, HRT, KNTE
NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 26, 2024 06:44 pm ET
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AA, NGM, MDC, KAMN
NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
Feb 26, 2024 03:44 pm ET
Kuehn Law Encourages AGTI, GLT, NGM, and AA Investors to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn...
Feb 26, 2024 11:41 am ET
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) to affiliates of The Column Group, LP for $1.55 in cash per share is fair to NGM shareholders.
Feb 26, 2024 10:37 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), Hi
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 26, 2024 09:03 am ET
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that it has entered into a definitive Agreement and Plan of Merger (the...
Feb 20, 2024 04:01 pm ET
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a...
Jan 17, 2024 04:47 pm ET
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret,...
Jan 09, 2024 08:00 am ET
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Nee
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced encouraging new data from an ongoing Phase 1 Part 1b study evaluating...
Jan 02, 2024 08:31 am ET
Thinking about buying stock in NGM Biopharmaceuticals, Syros Pharmaceuticals, Mereo BioPharma, BTCS Inc, or Sentage Holdings?
NEW YORK, Jan. 2, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NGM, SYRS, MREO, BTCS, and SNTG.
Nov 13, 2023 09:45 am ET
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today shared positive, comprehensive results from its Phase 2b ALPINE 4 trial of...
Nov 07, 2023 04:05 pm ET
NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate...
Nov 02, 2023 04:01 pm ET
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended...
Oct 11, 2023 04:05 pm ET
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to comprehensive results from the company’s Phase...
Sep 27, 2023 08:30 am ET
Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and A
Alexandria is well positioned to support companies in the growing area of AI-enhanced laboratory-based research and development, which is contributing to demand for advanced laboratory infrastructure requirements
Aug 03, 2023 04:01 pm ET
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
--Announced topline positive data from Phase 2b ALPINE 4 trial of aldafermin; study met its primary endpoint in patients with compensated cirrhosis (F4) due to NASH-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707,...
May 25, 2023 09:00 am ET
NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
May 08, 2023 04:05 pm ET
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Ma
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that results of a Phase 2 investigator-sponsored trial of aldafermin for...
May 04, 2023 04:05 pm ET
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended March 31,...
Mar 01, 2023 09:00 am ET
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate...
Feb 28, 2023 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the fourth quarter...
Jan 12, 2023 08:00 am ET
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan...
Jan 09, 2023 09:00 am ET
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today is providing an overview of highlights from 2022 and outlining its 2023 corporate...
Dec 12, 2022 07:00 pm ET
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on the poster presentation given on the Company’s first...
Dec 07, 2022 06:45 pm ET
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the presentation of preliminary data from the Phase 1 Part 1a monotherapy...
Nov 07, 2022 08:00 am ET
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to the Company’s lead myeloid reprogramming and...
Nov 04, 2022 08:00 am ET
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to the Company’s first disclosed preclinical...
Nov 03, 2022 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the...
Nov 03, 2022 01:00 pm ET
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Soc
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the presentation of findings from post-hoc analyses of its randomized,...
Oct 17, 2022 07:30 am ET
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy and safety results from its randomized, double-masked,...
Oct 16, 2022 04:30 pm ET
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in...
Sep 13, 2022 05:30 pm ET
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that updated preliminary findings from its Phase 1b dose escalation trial...
Sep 06, 2022 08:00 am ET
NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1a study with no dose-limiting toxicitiesTwo of five prostate...
Aug 15, 2022 08:00 am ET
NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that abstracts related to NGM120, an antagonist antibody product candidate...
Aug 04, 2022 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the...
Jun 30, 2022 08:00 am ET
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Siobhan Nolan Mangini, who has served as the company’s Chief...
Jun 23, 2022 04:05 pm ET
NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the fourth of four virtual R&D events on Wednesday, June 29,...
Jun 02, 2022 08:00 am ET
NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
May 24, 2022 04:05 pm ET
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the third of four virtual R&D events on Tuesday, May 31,...
May 12, 2022 08:00 am ET
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has initiated a Phase 1/1b clinical study of NGM438 for the treatment...
May 05, 2022 04:14 pm ET
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period...
Apr 20, 2022 04:05 pm ET
NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
Apr 20, 2022 09:00 am ET
NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the second of four virtual R&D events on Wednesday, April 27,...
Apr 08, 2022 08:00 am ET
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on two late-breaking poster presentations it will give on...
Mar 31, 2022 04:05 pm ET
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has dosed the first patient in a Phase 1/1b clinical trial of NGM831...
Mar 21, 2022 08:00 am ET
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the first of four virtual R&D events on Wednesday, March 30,...
Mar 08, 2022 04:13 pm ET
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that abstracts related to all three of the company’s myeloid reprogramming...
Mar 01, 2022 04:06 pm ET
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the full year and...
Feb 28, 2022 08:00 am ET
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate...
Feb 07, 2022 08:00 am ET
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Jan 20, 2022 08:00 am ET
NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
Jan 10, 2022 09:00 am ET
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided an overview of highlights from 2021 and its strategic priorities for 2022....
Jan 06, 2022 08:00 am ET
NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
Dec 06, 2021 08:00 am ET
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD...
Nov 09, 2021 06:30 am ET
NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
Nov 04, 2021 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period...
Sep 16, 2021 08:00 am ET
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that preliminary findings from its ongoing, open-label Phase 1a/1b dose...
Aug 23, 2021 08:00 am ET
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody...
Aug 05, 2021 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the period ending...
Jul 22, 2021 04:05 pm ET
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has completed enrollment in the Phase 2 CATALINA study, which is evaluating...
Jul 07, 2021 07:00 am ET
NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors
Approximately 180 patients expected to be enrolled in the Phase 1/2 Study-- SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and...
Jul 01, 2021 07:00 am ET
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases
NGM Biopharmaceuticals, Inc. (NGM) today announced that the company has entered into an amended and restated agreement with Merck, known as MSD outside the United States and Canada, to extend their ongoing collaboration through March 2024 but with...
Jun 07, 2021 08:00 am ET
NGM Bio to Present at Two Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
May 25, 2021 09:24 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Biopharmaceuticals, Inc. (“NGM” or “the Company”) (NASDAQ:
May 25, 2021 08:00 am ET
NGM Biopharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises NGM Biopharmaceuticals, Inc. ("NGM" or the "Company") (NASDAQ: NGM) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors...
May 24, 2021 03:09 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Biopharmaceuticals, Inc. (“NGM” or “the Company”) (NASDAQ:
May 24, 2021 07:00 am ET
NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
Study did not meet primary endpoint of fibrosis improvement by >- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported results from...
May 23, 2021 06:00 pm ET
NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg...
May 06, 2021 04:05 pm ET
NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the period ending...
Apr 28, 2021 04:15 pm ET
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today the nomination of Roger M. Perlmutter, M.D., Ph.D., to stand for election to...
Mar 04, 2021 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the periods ending...
Mar 02, 2021 08:00 am ET
NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has dosed the first patient in an expansion of its ongoing Phase 1b...
Feb 25, 2021 08:00 am ET
NGM Bio to Present at the Cowen 41st Annual Health Care Conference
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
Feb 09, 2021 08:00 am ET
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that additional data from its Phase 1 study of NGM621, an anti-complement C3...
Jan 12, 2021 04:05 pm ET
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today outlined its key achievements in 2020 and its strategic priorities for 2021. “2020 was...
Jan 05, 2021 09:54 pm ET
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the pricing of an underwritten public offering of 4,629,630 shares of its...
Jan 04, 2021 04:01 pm ET
NGM Bio Announces Proposed Offering of Common Stock
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that it has commenced an underwritten public offering of $100,000,000 of...
Dec 09, 2020 04:05 pm ET
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today disclosed its third oncology development candidate, NGM438, a novel antagonist antibody...
Nov 16, 2020 12:05 pm ET
NGM to Host Virtual R&D Day on December 9, 2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host a virtual R&D Day on December 9, 2020 at 12:00 pm ET. The R&D...
Nov 13, 2020 08:00 am ET
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that findings from its Phase 1 clinical study of NGM621, an anti-complement C3 antibody,...
Nov 12, 2020 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
Announced expansion of oncology portfolio with first immuno-oncology candidate, NGM707, a novel dual antagonist antibody inhibiting ILT2 and ILT4NGM has $287.9 million in cash, cash equivalents and marketable securities as of September 30,...
Nov 11, 2020 08:00 am ET
NGM Bio to Present at Three Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
Nov 05, 2020 08:00 am ET
NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that data from its Phase 1 study of NGM621, a potent anti-complement C3 antibody,...
Nov 04, 2020 08:00 am ET
NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with N
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that multiple aldafermin presentations, including a late-breaking oral presentation...
Oct 19, 2020 07:00 am ET
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the expansion of its oncology portfolio with its first immuno-oncology...
Aug 29, 2020 07:20 am ET
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollmen
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that final data from its 24-week Phase 2 study (Cohort 4) of aldafermin 1 mg...
Aug 18, 2020 08:00 am ET
NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that comprehensive data from its 24-week Phase 2 study (Cohort 4) of...
Aug 12, 2020 04:05 pm ET
NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
--$312.1 million in cash, cash equivalents and marketable securities as of June 30, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on...
Jul 31, 2020 08:00 am ET
NGM Bio to Present at Two Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an...
Jul 27, 2020 08:00 am ET
NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has initiated the Phase 2 CATALINA study, a multicenter, randomized,...
Jun 08, 2020 08:00 am ET
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the appointment of Carole Ho, M.D. to its Board of Directors. Dr. Ho currently...
May 29, 2020 04:05 pm ET
NGM Bio to Present at Two Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and...
May 27, 2020 04:05 pm ET
NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced the appointment of Siobhan Nolan Mangini as Chief Financial Officer (CFO). In her role as CFO,...
May 13, 2020 04:05 pm ET
NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results
-- Continuing enrollment in Phase 2b ALPINE 2/3 clinical study of aldafermin in NASH patients with F2-F3 fibrosis; topline data readout still targeted for first half of 2021 -- -- Sustaining progress across broad pipeline, which includes six...
May 08, 2020 04:05 pm ET
NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that, due to public health and safety concerns related to the coronavirus (COVID-19) pandemic, recommendations and orders from federal, state and local authorities, and to support the...
Mar 17, 2020 04:05 pm ET
NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
NGM Biopharmaceuticals, Inc. (NGM or the Company) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today reported financial results for the fourth quarter and year ended December 31, 2019 and...
Mar 09, 2020 04:30 pm ET
Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that, effective March 13, 2020, Aetna Wun Trombley, Ph.D. will step down as President and Chief...
Feb 25, 2020 08:00 am ET
NGM Bio to Present at Cowen and Company 40th Annual Health Care Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and...
Feb 24, 2020 08:00 am ET
NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced positive preliminary topline...
Feb 23, 2020 04:00 pm ET
NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, February 24, 2020 at 8:30 a.m. ET (5:30 a.m. PT) to discuss preliminary topline results from the 24-week double-blind, randomized, placebo-controlled...
Feb 11, 2020 08:00 am ET
NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the initiation of a Phase 1a/1b clinical study of NGM120, a first-in-class...
Dec 05, 2019 05:00 pm ET
NGM Bio Announces Appointment of Shelly Guyer to Board of Directors
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who...
Nov 14, 2019 08:00 am ET
NGM Bio to Present at the Stifel 2019 Healthcare Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present at the Stifel...
Nov 12, 2019 04:05 pm ET
NGM Reports Business Highlights and Third Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM or the Company) (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today reported...
Oct 29, 2019 07:00 am ET
NGM Bio Announces Appointment of Valerie Pierce as General Counsel
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the appointment of Valerie Pierce as Senior Vice President, General Counsel and Chief...
Oct 18, 2019 07:00 pm ET
NGM Bio to Present at Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that it will present at two upcoming conferences focused on drug research and...
Oct 07, 2019 08:00 am ET
NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced positive...
Oct 06, 2019 04:00 pm ET
NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 7, 2019 at 8:30 a.m. ET (5:30 a.m. PT) to discuss preliminary results from a planned, pre-specified interim analysis of the aldafermin 1 mg...
Oct 03, 2019 07:00 am ET
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting®
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative therapeutics for patients, today announced multiple aldafermin (NGM282) poster presentations at...
Aug 12, 2019 04:05 pm ET
NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results
--Completed enrollment of 1 mg cohort of 24-week Phase 2 study of NGM282 (aldafermin) in NASH patients; Planned data readouts over next 3 – 6 months-- --Robust clinical stage pipeline now spans novel drugs to address significant unmet needs in...
Jun 10, 2019 07:00 am ET
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Aetna Wun Trombley,...
Jun 05, 2019 07:00 am ET
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that it will present new data from a Phase 1b study of NGM313 at the 79th Scientific...
May 16, 2019 04:05 pm ET
NGM Bio Reports Recent Highlights and First Quarter 2019 Financial Results
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today provided a business update and reported first quarter 2019 financial results for the period...
Apr 08, 2019 04:30 pm ET
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative therapeutics for patients, today announced multiple presentations at European Association for the...
Apr 03, 2019 08:58 pm ET
NGM Bio Announces Pricing of Initial Public Offering
NGM Biopharmaceuticals, Inc. (“NGM”) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a price to the public of $16.00 per share. In addition, NGM has granted the underwriters a 30-day option to...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.